期刊文献+

IGF-ⅠR信号通路在西妥昔单抗抗HepG2细胞增殖中的作用

Role of IGF-ⅠR signaling pathway in the anti-proliferation of cetuximab to HepG2 cells
下载PDF
导出
摘要 目的探讨IGF-ⅠR信号通路在西妥昔单抗抗HepG2细胞增殖中的作用。方法选用浓度递增的西妥昔单抗(5~500)mg/mL、胰岛素样生长因子(IGF)(2.5~250)μmol/L及其抑制剂aIR3(2.5~250)μmol/L,单独或联合作用于HepG2细胞,观察IGF与aIR3对西妥昔单抗抗HepG2增殖的影响。结果细胞培养72 h后,单药西妥昔单抗对HepG2细胞增殖的抑制作用呈浓度依赖性,西妥昔单抗联合aIR3组增殖抑制率在相应浓度下均显著高于同浓度的西妥昔单抗组(均为P<0.01),IGF(10~250)μmol/L与西妥昔单抗(20~500)mg/mL联合组增殖抑制率均显著低于相应浓度的西妥昔单抗组(均为P<0.01)。结论 IGF-ⅠR通路可影响西妥昔单抗抗HepG2细胞增殖的作用,可能是肝癌细胞株对西妥昔单抗耐药的机制之一。 Objective To investigate the role of IGF- I R signaling pathway in the anti-proliferation of cetuximab to HepG2 cells. Methods Increasing concentrations of cetuximab (5-500) mg/mL, insulin-like growth factor (IGF) (2.5-250) μmol/L and its inhibitor aiR3 (2.5-250)μmol/L, alone or in combination were administrated to HepG2 cells. The inhibitory effects of the drugs on cell proliferation were observed. Results After 72 h cell culture, the single agent of cetuximab inhib- ited the proliferation of HepG2 cells in a dose-dependent manner. The growth inhibition rates of cetuximab combined aiR3 group at the corresponding concentrations were significantly higher than that of cetuximab group (all P 〈 0.01). However, the proliferation inhibition rates of IGF (10-250) μmol/L combined cetuximab (20-500) mg/mL were significantly lower than that of cetuximab group (all P 〈 0.01). Conclusion IGF- l R pathway can affect the anti-proliferation of cetuximab to HepG2 cells, which may be one of the mechanisms of hepatocellular carcinoma cell lines resistance to cetuximab.
出处 《中国现代医生》 2012年第25期2-4,共3页 China Modern Doctor
基金 2009年度浙江省湖州市第二批科技计划项目(2009YS06)
关键词 肝癌细胞株 表皮生长因子受体 西妥昔单抗 胰岛素样生长因子-Ⅰ受体 Hepatocellular carcinoma cell lines Epidermal growth factor receptor Cetuximab Insulin-like growth factor- I receptor
  • 相关文献

参考文献9

  • 1吕汪霞,马胜林.西妥昔单抗的临床研究新进展[J].医学综述,2010,16(9):1345-1348. 被引量:8
  • 2Jalal S,Waterhouse D,Edelman M J, et al. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I / 11 study from the Hoosier Oncology Group[J]. J Thorac Oncol,2009,4( 11 ) : 1420-1424.
  • 3Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling[J]. Cancer Res, 2002,62 ( 1 ) : 200 - 207.
  • 4Rubin Grandis J, Melhem MF, Gooding WE,et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival[J], J Natl Cancer Inst, 1998,90( 11 ) : 824-832.
  • 5徐立,张昌卿,冯凯涛,李锦清.肝细胞癌及癌旁肝组织EGFR和EGFR vⅢ的表达及其临床意义[J].中山大学学报(医学科学版),2006,27(4):467-471. 被引量:14
  • 6Mendelsohn J,Baselga J. Epidermal growth factor receptor targeting in cancer[J]. Semin Oncol, 2006,33 (4) : 369-385.
  • 7王洪波,陈晓光.EGFR抑制剂耐药机制研究的新进展[J].国际药学研究杂志,2007,34(5):347-350. 被引量:7
  • 8Hailey J,Maxwell E,Koukouras K,et al. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells[J]. Mol Cancer Ther,2002,1 (14) : 1349- 1353.
  • 9Lu Y,Zi X,Zhao Y,et al. Insulin-like growth factor- I receptor signal- ing and resistance to trastuzumab (Herceptin)[J]. J Natl Cancer Inst,2001,93 (24) : 1852-1857.

二级参考文献59

  • 1赵荫农,曹骥,吴飞翔,欧超,袁卫平,莫钦国,韦薇,李瑗,苏建家,梁安民.EGF mRNA和EGFR mRNA在肝细胞癌组织中的表达及其意义[J].癌症,2004,23(7):762-766. 被引量:11
  • 2欧超,吴飞翔,罗元,曹骥,赵荫农,袁卫平,李瑗,苏建家.表皮生长因子受体Ⅲ型突变体在肝细胞癌中的表达及意义[J].癌症,2005,24(2):166-169. 被引量:19
  • 3[1]Rubin-Grandis J,Melhem MF,Gooding WE,et al.Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival[J].J Natl Cancer Inst,1998,90(11):824-832.
  • 4[2]Mendelsohn J,Baselga J.Epidermal growth factor receptor targeting in cancer[J].Semin Oncol,2006,33(4):369-385.
  • 5[3]Astsaturov I,Cohen RB,Harari PM.EGFR-targeting monoclonal antibodies in head and neck cancer[J].Curr Cancer Drug Targets,2006,6(8):691-710.
  • 6[4]Ravindranath N,Wion D,Brachet P,et al.Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate[J].J Androl,2001,22(3):432-443.
  • 7[5]Viloria-Petit A,Crombet T,Jothy S,et al.Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo:a role for altered tumor angiogenesis[J].Cancer Res,2001,61(13):5090-5101.
  • 8[6]Viloria-Petit AM,Kerbel RS.Acquired resistance to EGFR inhibitors:mechanisms and prevention strategies[J].Int J Radiat Oncol Biol Phys,2004,58(3):914-926.
  • 9[7]Ciardiello F,Bianco R,Caputo R,et al.Antitumor activity of ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy[J].Clin Cancer Res,2004,10(2):784-793.
  • 10[8]Vallbohmer D,Zhang,W,Gordon,M,et al.Molecular determinants of cetuximab efficacy[J].J Clin Oncol,2005,23(15):3536-3544.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部